Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 and Ivosidenib in IDH1-Mutated AML or High-Risk MDS
NCT04493164Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2020
- Primary completion
- Jun 2028
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib, daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2020; status: recruiting.
02
Drugs
ivosidenibdaunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04493164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493164.